Timothy Miller, MD
Neurology · Saint Louis, MONPI 1255356671
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $76,554 of the $82,466 with a category attached, or 92.8%. Biogen accounts for 89.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $43,514 and has fallen 70.9% since, to $12,679 in 2025. Among neurology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $3298.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$74K
- Biomarin Pharmaceutical Inc.$5K
- Regeneron$2K
- Ionis Pharmaceuticals, Inc.$650
- Genentech, Inc.$500
Across 64 payments — averaging $5517.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Orion Corporation$94K
- Biogen$86K
- Amylyx Pharmaceuticals, Inc.$58K
- Tanabe Pharma America, Inc.$53K
- UCB SA$48K
- Biohaven Pharmaceutical Holding Company Ltd.$13K
What the payments were for
- Consulting fees$76,55493%
- Speaking & faculty fees$5,1406%
- Travel & lodging$7341%
- Food & beverage$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 13 | $74,154 |
| Biomarin Pharmaceutical Inc. | 4 | $5,413 |
| Regeneron | 2 | $1,750 |
| Ionis Pharmaceuticals, Inc. | 5 | $650 |
| Genentech, Inc. | 1 | $500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QALSODY$1,100
How this compares
$82,466 in reported general payments places this provider in the 90th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 14 | $704,482 |
| SkyclarysOmaveloxolone | 12 | $374,782 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $52,961 |
| Riluzole | 15 | $3,309 |
| Pyridostigmine Bromide | 27 | $1,309 |
| Mycophenolate Mofetil | 11 | $577 |
| Gabapentin | 29 | $405 |
| Baclofen | 19 | $386 |
| Prednisone | 19 | $193 |
| Sodium Chloride0.9 % Sodium Chloride | 14 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenSkyclarys | $74,154 | $374,78212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 381 neurology providers in Missouri.
Other neurology in Saint Louis
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Robert NaismithSaint Louis$677K
- Arun VaradhacharySaint Louis$273K
- Anne CrossSaint Louis$190K
- David HoltzmanSaint Louis$165K
- Ghazala HayatSaint Louis$155K
- Pratap ChandSaint Louis$139K
- Lee TempelSaint Louis$121K
- Salim ChahinSaint Louis$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.